Wonderful. That was extremely helpful. My last question is kind of a minor one for Tim. I was just wondering, so after the amendment that was filed last week, how much is left under the ATM right now?
I wanted to start off with the 510(k) for the Acuitas device. Can you give us a sense of what types of questions the FDA is asking? Are they questions that are easy to address? Or are these questions that might take some time to work on?
Bruce, thanks for the question. Evan Jones here, I'll answer that one. First, let me just say that the near-term delays are primarily a function of the state of Maryland having shut down all nonessential businesses. And so even though the FDA is capable and is working remotely, that's causing anticipated understandable near-term delay there. In terms of the remaining questions, without getting into a lot of the details, I can tell you that they're the type of questions that are related to product labeling and things like that.
Okay, great. That's very helpful. And then in terms of the supply of the BGI SARS-2 test, you said you've got some visibility there. Do you have any type of relationship in place where if you get -- if they get supply constrained, you get preferred status and the product can continue to flow to your customers?
That's a very good question. I would like to believe so. Is it contractual in writing? No. But I've been dealing with Chinese partners for many, many years. We were the first ones they called in January in Europe. We were the first ones they offered the commercial partnership opportunity to. Now, understandably, they're not relying on Curetis alone here in Europe, so we are one of several partners. But we have a very close dialogue with the European representatives, and we also have a direct communication channel to corporate headquarters in Shenzhen in China.
So far, they've been very good. They give us heads up on volumes inbound. They proactively ask, what's your next week's take? If only I knew, and I can tell you literally, we've been in a mode these last 48 hours where we've been short-selling product. I've sold kits that I knew we were going to get, and we did actually receive them this morning, but I sold some of those kits last Friday. So, so far, they -- again, they have made us a preferred partner. We hope that stays that way. And we obviously do our utmost to justify that trust and that relationship by getting those kits in the hands of distribution partners and into the market as quickly as possible.
What I can see from -- and again, it's only been a week, the first shipment. Second shipment was 10x the size of the first one. It's a safe assumption that the next shipment we're getting is yet again going to be larger. So we're definitely getting a feel for what's the weekly volume that we can safely put into our channels, and that number is likely going to be increasing. And so yes, I think we'll continue to benefit from this personal but also corporate relationship between Curetis and BGI as things get even crazier and even more hectic here.
Market Data 
Markets 
AI
